Drug Trial Radar · NCT00806546
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
Last checked: Nov 19, 2026Latest source record: Feb 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
514
Actual
Start
Feb 2009
Primary completion
May 2011
Study completion May 2011
Sponsor
- Lead sponsor
- NuPathe Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 11, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.
Conditions
- Migraine Disorders
Interventions
NP101Drug
NP101 study patch four hour application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subject Self-examination of Skin IrritationTime frame: 24 hours post patch application
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Irvine, California
Site not named
Newport Beach, California
Site not named
San Francisco, California
Site not named
Santa Monica, California
Site not named
Walnut Creek, California
Site not named
Fairfield, Connecticut
Site not named
Hallandale, Florida
Site not named
Ocala, Florida
Site not named
Sunrise, Florida
Site not named
Atlanta, Georgia
Site not named
Decatur, Georgia
Site not named
Savannah, Georgia
Site not named
Crestview Hills, Kentucky
Site not named
Ann Arbor, Michigan
Site not named
St Louis, Missouri
Site not named
Mount Vernon, New York
Site not named
Plainview, New York
Site not named
Greensboro, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Clarksville, Tennessee
Site not named
Dallas, Texas
Site not named
San Antonio, Texas
Site not named
Alexandria, Virginia
Site not named
Virginia Beach, Virginia
Site not named
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.